LONDON (Alliance News) - Pharmaceutical services company Clinigen Group PLC on Monday said its managed access unit has initiated a new programme for ixazomib for patients with multiple myeloma.
Ixazomib, an oral proteasome inhibitor for patients with multiple myeloma, a blood cancer, is developed and manufactured by Takeda Pharmaceutical Co Ltd, Japan's largest drug company.
The managed access programme will allow individual patients with multiple myeloma living outside the US to receive the drug in countries where it is not yet available.
No financial details were disclosed.
Shares in Clinigen were up 0.5% to 652.61 pence on Monday morning.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
